Regeneron Pharmaceuticals, Inc. (REGN)
Automate Your Wheel Strategy on REGN
With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REGN
- Rev/Share 137.501
- Book/Share 298.764
- PB 2.6114
- Debt/Equity 0.0874
- CurrentRatio 4.0633
- ROIC 0.0918
- MktCap 80579831680.0
- FreeCF/Share 40.0918
- PFCF 19.3967
- PE 17.659
- Debt/Assets 0.0674
- DivYield 0.0045
- ROE 0.1531
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | REGN | Truist | -- | Buy | -- | $798 | Nov. 24, 2025 |
| Initiation | REGN | HSBC Securities | -- | Buy | -- | $255 | Nov. 24, 2025 |
| Initiation | REGN | Scotiabank | -- | Sector Perform | -- | $650 | Nov. 13, 2025 |
| Initiation | REGN | Rothschild & Co Redburn | -- | Buy | -- | $890 | Aug. 14, 2025 |
| Downgrade | REGN | Argus | Buy | Hold | -- | -- | June 30, 2025 |
| Downgrade | REGN | Wells Fargo | Overweight | Equal Weight | -- | $580 | May 30, 2025 |
| Downgrade | REGN | RBC Capital Mkts | Outperform | Sector Perform | -- | $662 | May 30, 2025 |
| Upgrade | REGN | Citigroup | Neutral | Buy | -- | $700 | May 14, 2025 |
| Resumed | REGN | Cantor Fitzgerald | -- | Overweight | -- | $695 | April 22, 2025 |
| Upgrade | REGN | Leerink Partners | Market Perform | Outperform | $762 | $834 | Feb. 5, 2025 |
News
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
Read More
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
Read More
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Read More
This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead
Published: November 21, 2025 by: Investopedia
Sentiment: Neutral
November's Wall Street obsession hasn't been AI. It's been healthcare.
Read More
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. ( REGN ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Thanks so much, everyone. It's funny.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. ( REGN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 9:20 AM EST Company Participants Mark Hudson - Investor Relations Executive Isreal Lowy - Senior Vice President of Clinical Development Unit Head & Oncology Justin Holko Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Presentation Alexandria Hammond Wolfe Research, LLC Good morning, everybody. My name is Alex Hammond, and I'm the senior biopharma analyst here at Wolfe Research.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. ( REGN ) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman L. Sirulnik - Senior Vice President of Clinical Development Unit Head & Hematology David Gutstein Conference Call Participants Brian Abrahams - RBC Capital Markets, Research Division Tyler Van Buren - TD Cowen, Research Division David Risinger - Leerink Partners LLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Malcolm Hoffman …
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman Marion McCourt - Executive Vice President of Commercial Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Tyler Van …
Read More
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness
Published: October 28, 2025 by: Benzinga
Sentiment: Positive
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.
Read More
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Read More
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Read More
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
Read More
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Regeneron Pharmaceuticals catalysts could drive stock higher: analysts
Published: October 03, 2025 by: Proactive Investors
Sentiment: Positive
JP Morgan analysts see an “attractive setup” for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares, believing the company's Dupixent and Eylea drugs and cash on hand alone support valuation at current levels. In a note to clients on Friday, the analysts wrote that they expect several catalysts for the company over the next three to six months, including Phase 3 trial results for LAG3 melanoma treatment as well as several potential Eylea updates.
Read More
Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
Published: September 30, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's "Halftime Report" team detail their stock picks and final trades.
Read More
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.
Read More
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
Read More
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
Published: September 19, 2025 by: Reuters
Sentiment: Positive
Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial.
Read More
Regeneron's bone disorder treatment succeeds in late-stage trial
Published: September 17, 2025 by: Reuters
Sentiment: Positive
Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder that affects bone tissue has met the main goal of a late-stage trial.
Read More
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation
Read More
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Christopher Fenimore - Executive VP of Finance & CFO Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman Marion McCourt - Executive Vice President of Commercial Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.
Read More
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Published: September 08, 2025 by: Benzinga
Sentiment: Positive
Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.
Read More
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
Published: August 21, 2025 by: CNBC
Sentiment: Positive
Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is five years and $3.2 billion in the making.
Read More
About Regeneron Pharmaceuticals, Inc. (REGN)
- IPO Date 1991-04-02
- Website https://www.regeneron.com
- Industry Biotechnology
- CEO Leonard S. Schleifer
- Employees 15158